Literature DB >> 29571133

LC-MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure.

M Marcinkiewicz-Siemion1, M Ciborowski2, K Ptaszynska-Kopczynska1, A Szpakowicz1, A Lisowska1, M Jasiewicz1, E Waszkiewicz1, A Kretowski2, W J Musial1, K A Kaminski3.   

Abstract

Cardiac and extracardiac lipid metabolism is known to be significantly altered in the course of the heart failure with reduced ejection fraction (HF-REF), however the precise mechanisms are not fully elucidated. The aim of the study was to use of untargeted metabolomics to identify and validate changes in the blood metabolites profile, occurring as a result of HF-REF development. The analyses were performed first in the derivation set (36 chronic HF-REF patients and 19 controls without the disease) and repeated in validation cohort (31 chronic HF-REF patients and 20 controls). Independent analyses of both sets revealed statistically significant decline in intensities of phosphatidylcholine (PC): 34:4 and 36:5, lysophosphatidylcholine (lyso-PC): 14:0, 15:0, 18:0, 18:2, 20:3, lysophosphatidylethanolamine (lyso-PE): 18:1 and 18:2 in chronic HF-REF patients. More symptomatic patients and those with ischaemic etiology of HF-REF presented greater deficit in phospholipids (PLs) intensities. The decrease of identified PLs intensities (as compared to controls) correlated with decreased serum cholesterol level, impaired renal function, reduced exercise capacity, enhanced ventilatory response and metabolic parameters associated with altered fatty acids oxidation. In multiple regression analysis PLs deficit was significantly associated with age, carnitines serum intensity, renal function, uric acid, cholesterol level. In conclusion, HF-REF is associated with significant disturbances in phospholipids metabolism. Greater reduction in serum intensities of particular identified PLs is associated with older age, worse clinical condition, impaired oxidative muscle metabolism and enhanced catabolic status.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart failure; LC–MS; Metabolomics; Phospholipids

Mesh:

Substances:

Year:  2018        PMID: 29571133     DOI: 10.1016/j.jpba.2018.03.027

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  10 in total

1.  Association of Physical Activity With Bioactive Lipids and Cardiovascular Events.

Authors:  Rosangela A Hoshi; Yanyan Liu; Mohit Jain; Daniel I Chasman; Olga V Demler; Samia Mora; Heike Luttmann-Gibson; Saumya Tiwari; Franco Giulianini; Allen M Andres; Jeramie D Watrous; Nancy R Cook; Karen H Costenbader; Olivia I Okereke; Paul M Ridker; JoAnn E Manson; I-Min Lee; Manickavasagar Vinayagamoorthy; Susan Cheng; Trisha Copeland
Journal:  Circ Res       Date:  2022-07-19       Impact factor: 23.213

2.  Reduced Immunity Regulator MAVS Contributes to Non-Hypertrophic Cardiac Dysfunction by Disturbing Energy Metabolism and Mitochondrial Homeostasis.

Authors:  Qian Wang; Zhenzhen Sun; Shihan Cao; Xiuli Lin; Mengying Wu; Yuanyuan Li; Jie Yin; Wei Zhou; Songming Huang; Aihua Zhang; Yue Zhang; Weiwei Xia; Zhanjun Jia
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

3.  Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker.

Authors:  Tarek Bekfani; Mohamed Bekhite; Sophie Neugebauer; Steffen Derlien; Ali Hamadanchi; Jenny Nisser; Marion S Hilse; Daniela Haase; Tom Kretzschmar; Mei-Fang Wu; Michael Lichtenauer; Michael Kiehntopf; Stephan von Haehling; Peter Schlattmann; Gabriele Lehmann; Marcus Franz; Sven Möbius-Winkler; Christian Schulze
Journal:  Cells       Date:  2022-05-18       Impact factor: 7.666

4.  Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure.

Authors:  M Marcinkiewicz-Siemion; M Kaminski; M Ciborowski; K Ptaszynska-Kopczynska; A Szpakowicz; A Lisowska; M Jasiewicz; E Tarasiuk; A Kretowski; B Sobkowicz; K A Kaminski
Journal:  Sci Rep       Date:  2020-01-10       Impact factor: 4.379

5.  Exploration the Mechanism of Doxorubicin-Induced Heart Failure in Rats by Integration of Proteomics and Metabolomics Data.

Authors:  Yu Yuan; Simiao Fan; Lexin Shu; Wei Huang; Lijuan Xie; Chenghao Bi; Hongxin Yu; Yuming Wang; Yubo Li
Journal:  Front Pharmacol       Date:  2020-12-10       Impact factor: 5.810

Review 6.  Mitochondrial Homeostasis Mediates Lipotoxicity in the Failing Myocardium.

Authors:  Tom Kretzschmar; Jasmine M F Wu; P Christian Schulze
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

7.  Multi-Timepoint Metabolic Fingerprinting of a Post-Episode Period of Hypoglycemia and Ketoacidosis Among Children With Type 1 Diabetes.

Authors:  Beata Małachowska; Karolina Pietrowska; Wojciech Młynarski; Agnieszka Szadkowska; Adam Krętowski; Michał Ciborowski; Wojciech Fendler
Journal:  Front Mol Biosci       Date:  2022-06-23

8.  Sustained Endurance Training Leads to Metabolomic Adaptation.

Authors:  Astrid Weiss; Katharina Alack; Stephan Klatt; Sven Zukunft; Ralph Schermuly; Torsten Frech; Frank-Christoph Mooren; Karsten Krüger
Journal:  Metabolites       Date:  2022-07-16

9.  Physiological extremes of the human blood metabolome: A metabolomics analysis of highly glycolytic, oxidative, and anabolic athletes.

Authors:  Daniela Schranner; Martin Schönfelder; Werner Römisch-Margl; Johannes Scherr; Jürgen Schlegel; Otto Zelger; Annett Riermeier; Stephanie Kaps; Cornelia Prehn; Jerzy Adamski; Quirin Söhnlein; Fabian Stöcker; Florian Kreuzpointner; Martin Halle; Gabi Kastenmüller; Henning Wackerhage
Journal:  Physiol Rep       Date:  2021-06

10.  Comprehensive plasma metabolites profiling reveals phosphatidylcholine species as potential predictors for cardiac resynchronization therapy response.

Authors:  Shengwen Yang; Yiran Hu; Junhan Zhao; Ran Jing; Jing Wang; Min Gu; Hongxia Niu; Liang Chen; Wei Hua
Journal:  ESC Heart Fail       Date:  2020-11-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.